Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5  Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

ConclusionsContinued treatment with ixekizumab provided long-term sustained scalp clearance over 5  years to patients with moderate-to-severe plaque psoriasis and baseline scalp involvement, and holistic improvements occurred across clinical outcomes, patient-reported outcomes, and quality of life.Clinical Trial NumbersNCT01474512 (UNCOVER-1), NCT01597245 (UNCOVER-2), and NCT01646177 (UNCOVER-3).
Source: Dermatology and Therapy - Category: Dermatology Source Type: research